KRYS — Krystal Biotech, Inc.

Summary of Krystal Biotech Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Revenue: VYJUVEK net revenue for Q3 2025 was $97.8 million, showing continued growth, including contributions from the recent launch in Germany.
• Cumulative Revenue: Total net VYJUVEK revenues since launch exceeded $623 million.
• Gross Margin: Reported gross margin was 96%, an increase from 93% in the previous quarter, attributed to manufacturing process optimizations in the U.S.
• Expenses: R&D expenses were $14.6 million, while G&A expenses totaled $37.6 million, including $13.2 million in non-cash stock-based compensation.
• Net Income: Reported net income for the quarter was $79.4 million, translating to $2.74 per basic share and $2.66 per diluted share, boosted by a one-time tax benefit.
• Cash Position: The company ended the quarter with over $864 million in cash and investments.

2. Strategic Updates and Business Highlights

• Product Launches: VYJUVEK has been launched in Germany, France, and Japan, with positive initial traction and broad prescribing patterns observed.
• Reimbursement Approvals: Over 615 reimbursement approvals in the U.S., with more than 40 new approvals added since the last earnings call.
• Clinical Pipeline Expansion: Initiated a new clinical program for Hailey-Hailey disease and accelerated enrollment in existing programs, including KB801 for NK and KB407 for cystic fibrosis.
• FDA Label Update: The updated VYJUVEK label now includes DEB patients from birth, enhancing its market position.

3. Forward Guidance and Outlook

• Revenue Expectations: The company anticipates continued growth in VYJUVEK revenues, particularly as European launches gain momentum. However, they will not provide specific revenue guidance for 2026 due to the variability in launches.
• Clinical Milestones: Upcoming readouts expected in cystic fibrosis (KB407) by year-end and further data from NK and ophthalmology programs in 2026.

4. Bad News, Challenges, or Points of Concern

• Market Penetration: While there is optimism about U.S. and European launches, the company noted that revenue may experience quarter-to-quarter variability as they build their market presence.
• Ex-U.S. Sales Growth: Initial contributions from Germany were modest, and the company expects a gradual increase rather than a rapid uptake in new markets.
• Manufacturing Process Approval: The optimized manufacturing process has not yet been approved for products sold outside the U.S., which may affect future gross margins as international sales grow.

5. Notable Q&A Insights

• Ex-U.S. Strategy: The focus is on expanding the breadth of prescribers in Europe, particularly in centers of excellence, to facilitate patient access.
• NK Program Enrollment: Enrollment is ongoing, with expectations to have most sites operational by year-end. Interim data is targeted for mid-2026.
• Cystic Fibrosis Data: The company aims to report on at least three null patients, focusing on molecular correction as a key success metric.
• Pricing Strategy: Pricing negotiations vary by country, with Germany allowing free pricing for the first six months, while France's pricing discussions are ongoing.

Overall, Krystal Biotech demonstrated strong financial performance and strategic advancements in Q3 2025, with a focus on expanding their market presence and clinical pipeline, despite facing challenges in international sales growth and regulatory approvals.